Shire, and Santaris Extend Alliance to Develop LNA-drugs
Santaris Pharma and Shire have extended their partnership in the rare genetic disease space.
Santaris Pharma, a biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, has extended its existing partnership with Shire for treatments for rare genetic diseases.
Under the terms of the extended agreement, Shire will have the right to nominate additional collaboration targets for drug discovery and development. Santaris will receive an upfront payment and, consistent with the initial agreement, is eligible for research support, pre-clinical, clinical, and sales milestones, as well as royalties on each product emerging from the collaboration.
Source: Santaris Pharma
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
